Nabla Bio is an antibody design company. The company's AI-first protein design platform enables rapid engineering of best-in-class antibody therapeutics. The foundational technology was developed by CEO Surge Biswas, academic Co-Founder George Church and their team at Harvard, and has advanced the field of machine learning-guided protein modeling and design.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 12/06/21 | $11,000,000 | Seed |
Cantos Ventures Fifty Years Zetta Venture Partners  | undisclosed |
| 05/14/24 | $26,000,000 | Series A |
AstraZeneca Bristol Myers Squibb Radical Ventures Takeda Ventures | undisclosed |
